Showing 5331-5340 of 10176 results for "".
- Allergan Reiterates its Belief that Valeant's Business Model is Unsustainablehttps://practicaldermatology.com/news/20140616-allergan_reiterates_its_belief_that_valeants_business_model_is_unsustainable/2459204/Allergan, Inc. (NYSE: AGN) ("Allergan" or the "Company") today reiterated the Company's concern regarding Valeant Pharmaceuticals International, Inc.'s ("Valeant") unsustainable business model, which relies on serial acquisitions and cost reductions, as opposed to top-line revenue growth and operati
- Presentation: PV-10 decreases Melanoma Cells in Tumors and Boosts T-Cellshttps://practicaldermatology.com/news/20140407-presentation_pv-10_decreases_melanoma_cells_in_tumors_and_boosts_t-cells/2459277/Treatment with Provectus Biopharmaceuticals, Inc.'s PV-10 produces a significant decrease in melanoma cells in tumors 7-14 days after treatment, new data show. The data were presented by researchers at the Moffitt Cancer Center at the American Association for Cancer Research Annual Meeting in Sa
- Data for PV-10 in Melanoma to be Presented at European Cancer Congresshttps://practicaldermatology.com/news/20130913-data_for_pv-10_in_melanoma_to_be_presented_at_european_cancer_congress/2459461/Analysis of data from Provectus Pharmaceuticals, Inc.'s completed Phase 2 study of intralesional PV-10 in metastatic melanoma will be presented at the upcoming European Cancer Congress (ECCO 17- ESMO-38 - ESTRO 32), taking place September 27 through
- Colorescience Expands Executive Teamhttps://practicaldermatology.com/news/20130531-colorescience_expands_executive_team/2459526/Colorescience appointed former SkinMedica CEO, Mary Fisher, who joins the brand in the same capacity. She will also serve on the Company's Board of Directors, which is chaired by David Hale of Hale BioPharma Ventures, LLC. Josie Juncal, Chief Commercial Officer for
- Merz Makes Offer for Obagihttps://practicaldermatology.com/news/20130402-merz_makes_offer_for_obagi/2459576/With an unexpected $383.5 million bid, Merz Pharma Group formally proposed to acquire Obagi Medical Products, outdoing rival Valeant's bid for Obagi announced late last month and reported in yesterday's edition of DermWire. Merz sent a letter to Obagi Medical Products Inc.'s board offering to buy al
- MBA Aesthetics Course Finalizes Facultyhttps://practicaldermatology.com/news/20121017-mba_aesthetics_course_finalizes_faculty/2459703/“Mastering the Business of Aesthetics,” a one-day course taking place on October 27, will offer attendees insight on various clinical and financial elements of aesthetics practice. The faculty includes Paul S. Nassif, MD, FACS, Melanie Palm, MD, MBA, Nissan Pilest, MD, Robert James Troell, MD, FASC,
- La Roche-Posay Awards Two Researchershttps://practicaldermatology.com/news/20120514-la_roche-posay_awards_two_researchers/2459803/At its seventh annual North American Foundation Research Awards, La Roche-Posay honored winners Sarina B. Elmariah, MD, PhD and Marie S. Tuttle, MD. Both researchers received a $10,000 grant to continue dermatological research and were honored at t
- Study: Itch and Rash Severity Linked to Biologic Use in Eczemahttps://practicaldermatology.com/news/itch-and-rash-severity-linked-to-biologic-use-in-eczema-paper/2484499/Data from a recent pre-proof in the Journal of the American Academy of Dermatology highlights that both itch and lesion severity independently predict biologic treatment initiation in patients with moderate-to-severe atopic de
- FDA Accepts sNDA for ZORYVE Cream 0.3% in Children Aged 2 to 5https://practicaldermatology.com/news/fda-accepts-snda-for-zoryve-cream-03-in-children-ages-25/2484497/The US Food and Drug Administration (FDA) has accepted Arcutis Biotherapeutics’ supplemental New Drug Application (sNDA) seeking an expanded indication for ZORYVE® (roflumilast) cream 0.3% to include children ages 2 to 5 with plaque psoriasis.
- Arcutis Completes Enrollment for INTEGUMENT-INFANT Studyhttps://practicaldermatology.com/news/arcutis-completes-enrollment-for-integument-infant-study/2484474/Arcutis Biotherapeutics announced the completion of patient enrollment for the INTEGUMENT-INFANT phase 2 study, according to a press release from the company. Researchers for INTEGUMENT-INFANT will be evaluating ZORYVE® (roflum